Objective: A locally advanced Gleason 4 + 4 prostate cancer patient who was on self-medication with intermittent anti-androgen monotherapy (iAAm) over 14 years suggested that raised testosterone was not dangerous and this suggestion needed investigating. Patients: Others who were on AA continuously were recruited to ongoing audit of intermittent hormone therapy (IHT) and iAAm outcomes were compared with intermittent LHRH therapy (iLHRH or iMAB). Results: Between 1994 and 2007, 111 patients sought IHT because of side effects of treatment. Forty-two M0 patients received IHT with iLHRHm or iMAB and 33 received iAAm (31 of these were M0). PSA nadir below 4 was necessary for entry. Overall survival was 87, 72 and 67% with iAAm and 73, 56 and 43% with iLHRH/MAB at 5, 8 and 10 years respectively. Overall survival was 61, 55 and 33% continued on iAAm and 56, 41, and 32% on iLHRH/MAB at 5, 8, and 10 years respectively. Multivariable analysis and matched case control analysis confirm that the maintenance of advantage for iAAm Testosterone levels in patients on iAAm compared to iLHRH therapy was more intense throughout treatment. Conclusion: These results complement recent progress in using bipolar androgen therapy to reverse castration resistance and add to the increasing acceptance that controlled testosterone exposure might be relevant in hormone-naïve patients.

Keywords:
Intermittent, Anti-androgen, Bipolar androgen therapy, Prostate cancer
1.
Shaw GL, et al: International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int 2007; 99: 1056–1065.
2.
Niraula S, Le LW, Tannock IF: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 2013; 31: 2029–2036.
3.
Sciarra A, et al: Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013; 64: 722–730.
4.
Hussain M, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314–1325.
5.
Calais da Silva FE, et al: Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269–1277.
6.
Calais da Silva F, et al: Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. Eur Urol 2014; 66: 232–239.
7.
Crook JM, et al: Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367: 895–903.
8.
Sciarra A, et al: Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013; 64: 722–730.
10.
Shaw GL, et al: Patient designed therapy provides possible “natural” selection evidence for testosterone as differentiating agent for high-grade prostate cancer. Br J Med Surg Urology 2009; 2: 171–173.
11.
Oliver RT, Williams G, Paris AM, Blandy JP: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997; 49: 79–82.
12.
Lane TM, et al: Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004; 73: 117–122.
13.
Oliver RT, Gallagher CJ: Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Cancer Surv 1995; 23: 191–207.
14.
Bhattacharyya M, et al: Dexamethasone as an alternative to cortisone in combination with stilboestrol for hormone refractory prostate cancer. Br J Cancer 2003; 88(suppl 1):S62–S147.
15.
Shamash J, et al: A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer 2010; 116: 3595–3602.
16.
Shamash J, et al: A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol. Br J Cancer 2011; 104: 620–628.
17.
Shamash J, et al: Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding. Br J Cancer 2005; 92: 36–40.
18.
Dancey G, et al: A phase 2 study of chlorambucil and lomustine (CL56) in the treatment of absolute hormone refractory prostate cancer. Br J Cancer 2003; 88(suppl 1):S61–143.
19.
Shamash J, et al: A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 2008; 98: 22–24.
20.
Akakura K, et al: Effects of intermittent androgen suppression on androgen dependent tumors. Cancer 1993; 71: 2782–2790.
21.
Sato N, et al: Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 139–146.
22.
Tyrrell CJ, et al: A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447–456.
23.
Sato N, Gleave ME, Bruchovsky N: Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCap prostate tumour model. J Steroid Biochem Mol Biol 1996; 58: 139–146.
24.
Huggins C: Effect of orchiectomy and irradiation on cancer of the prostate. Ann Surg 1942; 115: 1192–1200.
25.
Eaton NE, Reeves GK, Appleby PN, Key TJ: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999; 80: 930–934.
26.
Ross RK, et al: 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887–889.
27.
Klap J, Schmid M, Loughlin KR: The relationship between total testosterone levels and prostate cancer: a review of the continuing controversy. J Urol 2015; 193: 403–413.
28.
Harper ME, Pierrepoint CG, Griffiths K: Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984; 20: 477–482.
29.
Hyde Z, et al: Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol Biomarkers Prev 2012; 21: 1319–1329.
30.
Pierorazio PM, et al: Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore longitudinal study of aging. BJU Int 2010; 105: 824–829.
31.
Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672.
32.
Porcaro AB, et al: Association between basal total testosterone levels and tumor upgrading in low and intermediate risk prostate cancer. Urol Int 2017; 99: 215–221.
33.
San Francisco IF, Regan MM, Dewolf WC, Olumi AF: Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006; 175: 1341–1345.
34.
San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A: Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int 2014; 114: 229–235.
35.
Hussain SA, Weston R, Stephenson RN, George E, Parr NJ: Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 2003; 92: 690–694.
36.
Feneley MR, Carruthers M: Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med 2012; 9: 2138–2149.
37.
Debruyne FM, et al: Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men. BJU Int 2017; 119: 216–224.
38.
Loeb S, et al: Testosterone replacement therapy and risk of favorable and aggressive prostate cancer. J Clin Oncol 2017; 35: 1430–1436.
39.
Boyle P, et al: Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis. BJU Int 2016; 118: 731-741.
40.
Morris MJ, et al: Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56: 237–244.
41.
Tunn UW, Canepa G, Kochanowsky A, Kienle E: Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Prostate Cancer Prostatic Dis 2012; 15: 296–302.
42.
Stoll BA: Hypothesis: breast cancer regression under oestrogen therapy. Br Med J 1973; 3: 446–450.
43.
Isaacs JT, et al: Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate 2012; 72: 1491–1505.
44.
Schweizer MT, et al: Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med 2015; 7: 269ra262.
45.
Schweizer MT, et al: Bipolar androgen therapy for men with androgen ablation naive prostate cancer: results from the phase II BATMAN study. Prostate 2016; 76: 1218–1226.
46.
James ND, Sydes MR, Clarke NW, Mason MA, et al: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE). Lancet 2016; 387: 1163–1177.
47.
Koivisto P, et al: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314–319.
48.
Litvinov IV, De Marzo AM, Isaacs JT: Is the Achilles’ heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003; 88: 2972–2982.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.